Paul M. Michael
Voorzitter bij CURATIVE BIOTECHNOLOGY, INC.
Actieve functies van Paul M. Michael
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| CURATIVE BIOTECHNOLOGY, INC. | Voorzitter | 11-02-2021 | - |
| President | 11-02-2021 | - | |
| Directeur/Bestuurslid | - | 11-02-2021 | |
| Algemeen Directeur | - | 11-02-2021 |
Loopbaan van Paul M. Michael
Eerdere bekende functies van Paul M. Michael
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| PALISADE BIO, INC. | Oprichter | - | - |
Nobelpharma Co., Ltd.
 Nobelpharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Nobelpharma Co., Ltd. provides research and development of pharmaceuticals for unmet needs. Its product line encompasses orphan drugs, medicines used for additional efficacy, and pediatric medicines. The company was founded on June 6, 2003 and is headquartered in Tokyo, Japan. | Oprichter | - | - |
Statistieken
Internationaal
| Verenigde Staten | 3 |
| Japan | 2 |
Operationeel
| Founder | 2 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sectoraal
| Health Technology | 3 |
| Distribution Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CURATIVE BIOTECHNOLOGY, INC. | Distribution Services |
| Bedrijven in privébezit | 2 |
|---|---|
Nobelpharma Co., Ltd.
Nobelpharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Nobelpharma Co., Ltd. provides research and development of pharmaceuticals for unmet needs. Its product line encompasses orphan drugs, medicines used for additional efficacy, and pediatric medicines. The company was founded on June 6, 2003 and is headquartered in Tokyo, Japan. | Health Technology |
Seneca Biopharma, Inc.
 Seneca Biopharma, Inc. BiotechnologyHealth Technology Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD. | Health Technology |
- Beurs
- Insiders
- Paul M. Michael
- Ervaring
